Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myelodysplastic Syndrome (MDS): early-phase trial registry
5 of 20 indexed Myelodysplastic Syndrome (MDS) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #848 of 28,707 conditions by registered trial count.
20 US clinical trials · 5 currently recruiting · #848 of 28,707 conditions by registered trial count
Myelodysplastic Syndrome (MDS): 20 US clinical trials tracked, 5 recruiting.
Myelodysplastic Syndrome (MDS) is the subject of 20 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most active sponsor is St. Jude Children's Research Hospital, running 3 of these trials.
Enrollment posture brief
Registry condition myelodysplastic-syndrome-mds
OPEN 5 | RECR 25% | LATE 2 | EARLY 17 | RANK #848 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Myelodysplastic Syndrome (MDS) lists 5 open slots (25% of 20 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myelodysplastic Syndrome (MDS) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myelodysplastic Syndrome (MDS) is recruiting below its size-band peers.
5 of 20 indexed trials (25%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Myelodysplastic Syndrome (MDS) research.
St. Jude Children's Research Hospital accounts for 3 of 20 trials (15%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Myelodysplastic Syndrome (MDS) trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 20 trials that report a genuine target (sentinel values excluded). 16 of those (80%) plan for fewer than 100 participants.
-
Myelodysplastic Syndrome (MDS) research is mostly interventional.
20 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
20 total, page 1 of 1
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Children's Hospital Medical Center, Cincinnati
NCT02143830
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Cullinan Therapeutics
NCT05143996
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
M.D. Anderson Cancer Center
NCT06548230
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
National Heart, Lung, and Blood Institute (NHLBI)
NCT03173937
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
medac
NCT05534620
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
AbbVie
NCT04401748
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Eli Lilly and Company
NCT04603001
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
St. Jude Children's Research Hospital
NCT02790515
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
Jacqueline Garcia, MD
NCT03613532
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Diane George
NCT02061800
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
NCT02793544
Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies
St. Jude Children's Research Hospital
NCT00186823
Improving Blood Stem Cell Collection and Transplant Procedures
National Heart, Lung, and Blood Institute (NHLBI)
NCT01517035
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
Center for International Blood and Marrow Transplant Research
NCT01772953
Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
Gamida Cell
NCT01816230
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
St. Jude Children's Research Hospital
NCT02212561
TPO-Mimetic Use in Children for Hematopoietic Failure
Anjali Sharathkumar
NCT04478227
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
National Heart, Lung, and Blood Institute (NHLBI)
NCT00488592
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Massachusetts General Hospital
NCT01758042
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
Joanne Kurtzberg, MD
NCT00673114
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 5 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Myelodysplastic Syndrome (MDS) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myelodysplastic Syndrome (MDS) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myelodysplastic Syndrome (MDS) page
20 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Myelodysplastic Syndrome (MDS) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- St. Jude Children's Research Hospital sponsors the most Myelodysplastic Syndrome (MDS) trials on record, review their full trial history before evaluating a specific study. See St. Jude Children's Research Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myelodysplastic Syndrome (MDS) condition card totals 20 registered trials; most-linked intervention Fludarabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.